PDE5A encodes phosphodiesterase type 5, a cGMP-specific phosphodiesterase that catalyzes hydrolysis of cyclic GMP to 5'-GMP, thereby regulating intracellular cGMP levels generated by nitric oxide signaling 1. The gene produces three isoforms (PDE5A1, PDE5A2, PDE5A3) from two alternate promoters, with tissue-specific expression patterns 2. PDE5A1 and PDE5A2 are ubiquitously expressed, while PDE5A3 is predominantly found in tissues with substantial smooth muscle 2. Clinically, PDE5A inhibitors (sildenafil, vardenafil, tadalafil) represent the most successful class of phosphodiesterase-selective therapeutics 3. These agents effectively treat erectile dysfunction by increasing penile blood flow during sexual stimulation 45. Beyond erectile dysfunction, PDE5A inhibition shows therapeutic potential in pulmonary arterial hypertension, where sildenafil reduces vascular remodeling and improves hemodynamics 6. Emerging evidence suggests PDE5A upregulation in bipolar disorder basal ganglia contributes to neuroinflammation and disease-like behaviors, which can be reversed by PDE5A inhibitors like tadalafil 7. Additionally, PDE5A is highly expressed in skeletal tissue, and preclinical data support potential therapeutic applications of PDE5A inhibitors in osteoporosis treatment by enhancing the NO-cGMP-PKG osteoanabolic pathway 8.